MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
100.27
-0.40
-0.40%
After Hours: 99.48 -0.79 -0.79% 19:56 11/13 EST
OPEN
100.32
PREV CLOSE
100.67
HIGH
101.23
LOW
99.26
VOLUME
2.28M
TURNOVER
--
52 WEEK HIGH
134.00
52 WEEK LOW
61.23
MARKET CAP
11.43B
P/E (TTM)
25.52
1D
5D
1M
3M
1Y
5Y
1D
Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals
NASDAQ · 1d ago
Why Is Halozyme Therapeutics (HALO) Drawing Fresh Attention Today?
Simply Wall St · 2d ago
What Halozyme Therapeutics Shareholders Got Right
Simply Wall St · 3d ago
Halozyme Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley
Dow Jones · 3d ago
Halozyme Therapeutics Price Target Raised to $109.00/Share From $105.00 by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Raises Price Target to $109
Benzinga · 3d ago
Halozyme downgraded at Morgan Stanley on valuation
Seeking Alpha · 3d ago
Nvidia downgraded, Mercury Systems upgraded: Wall Street’s top analyst calls
TipRanks · 3d ago
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.